These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2861470)

  • 1. Budipine and the MPTP binding site.
    Przuntek H; Russ H
    Lancet; 1985 Jul; 2(8445):35-6. PubMed ID: 2861470
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds.
    Markey SP; Schmuff NR
    Med Res Rev; 1986; 6(4):389-429. PubMed ID: 3534484
    [No Abstract]   [Full Text] [Related]  

  • 3. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 4. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.
    Javitch JA; Uhl GR; Snyder SH
    Proc Natl Acad Sci U S A; 1984 Jul; 81(14):4591-5. PubMed ID: 6611553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
    Jenner P; Rose S; Nomoto M; Marsden CD
    Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
    [No Abstract]   [Full Text] [Related]  

  • 7. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
    Mizukawa K; Ogawa N; Sora YH
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin colour, MPTP, and Parkinson's disease.
    Lerner MR; Goldman RS
    Lancet; 1987 Jul; 2(8552):212. PubMed ID: 2885659
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lipid peroxidation in the caudate nuclei in experimental parkinsonian syndrome].
    Kucherianu VG; Atadzhanov MA; Nikushkin EV; Zagorevskiĭ VA; Sharkova LM
    Biull Eksp Biol Med; 1989 Jan; 107(1):39-41. PubMed ID: 2783652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans.
    Lydén A; Bondesson U; Larsson BS; Lindquist NG
    Acta Pharmacol Toxicol (Copenh); 1983 Nov; 53(5):429-32. PubMed ID: 6606936
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Parkinson disease].
    Schlagmann C; Remien J
    Klin Wochenschr; 1986 Oct; 64(19):939-42. PubMed ID: 3491248
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue.
    Kornhuber J; Herr B; Thome J; Riederer P
    J Neural Transm Suppl; 1995; 46():131-7. PubMed ID: 8821048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain enzyme is the target of drug toxin.
    Lewin R
    Science; 1984 Sep; 225(4669):1460-2. PubMed ID: 6433484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.